Revenue: As of FY2025 Q3, the actual value is USD 116.74 M.EPS: As of FY2025 Q3, the actual value is USD -0.27.EBIT: As of FY2025 Q3, the actual value is USD -2.689 M.<h3>Segment Revenue</h3><ul><li>GeneDx: Revenue for the three months ended September 30, 2025, was $114.7 million, compared to $76.6 million for the same period in 2024. For the nine months ended September 30, 2025, revenue was $303.6 million, compared to $207.0 million in 2024.</li><li>Other: Revenue for the three months ended September 30, 2025, was $2.0 million, compared to $0.3 million for the same period in 2024. For the nine months ended September 30, 2025, revenue was $3.0 million, compared to $2.8 million in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: For the three months ended September 30, 2025, gross profit was $84.5 million, compared to $47.8 million in 2024. For the nine months ended September 30, 2025, gross profit was $213.9 million, compared to $128.2 million in 2024.</li><li>Net Loss: For the three months ended September 30, 2025, net loss was $7.6 million, compared to $8.3 million in 2024. For the nine months ended September 30, 2025, net loss was $3.4 million, compared to $57.7 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash provided by operating activities for the nine months ended September 30, 2025, was $36.4 million, compared to net cash used of - $25.3 million in 2024.</li><li>Investing Activities: Net cash used in investing activities for the nine months ended September 30, 2025, was - $50.4 million, compared to - $29.6 million in 2024.</li><li>Financing Activities: Net cash provided by financing activities for the nine months ended September 30, 2025, was $24.8 million, compared to $13.1 million in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Test Volume: During the three months ended September 30, 2025, 25,702 exome and genome tests were resulted, representing 43% of all test results, compared to 19,262 tests (33%) in 2024. For the nine months ended September 30, 2025, 69,510 tests were resulted, representing 41% of all test results, compared to 53,871 tests (31%) in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue focusing on increasing the adoption of its services, expanding coverage and reimbursement, and lowering the costs associated with performing tests. The company also aims to leverage its platforms to develop a pipeline of future disease-specific research and diagnostic and therapeutic products and services.</li><li>Non-Core Business: The company has exited its reproductive and women’s business and its somatic tumor testing business to focus on its core areas.</li></ul>

GeneDx - CW27 | 10-Q: FY2025 Q3 Revenue: USD 116.74 M